biotech / news / / Reuters
Amgen sells tarlatamab in its home market under the name Imdelltra.
Tarlatamab is a targeted immunotherapy for extensive-stage small cell lung cancer post-chemotherapy.
KEY POINTS
- Amgen markets tarlatamab as Imdelltra in the United States.
- Tarlatamab is a bispecific antibody that links cancer cells and immune cells for targeted killing.
- Analysts estimate tarlatamab could generate over $2 billion in annual sales for Amgen.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →